Search
for

    Sort by

    Research 691–720 of 1000+

    1. How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach Dermatology and Therapy · 2026
    2. Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience Immunological Medicine · 2026
    3. Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review Frontiers in Immunology · 2026
    4. Gastric Trichobezoar in a 2‐Year‐Old Girl With Severe Malnutrition and Social Risk: A Case Report Journal of Paediatrics and Child Health · 2026
    5. Greater susceptibility to telogen effluvium in the setting of severe COVID-19 infection: findings from a retrospective cohort study Archives of Dermatological Research · 2026
    6. X-linked Recessive Ectodysplasin A Mutations Induced Hypohidrotic Ectodermal Dysplasia and Severe Atopic Dermatitis Successfully Treated with Dupilumab Acta Dermato Venereologica · 2026
    7. Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort Dermatologic Therapy · 2026
    8. A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes Journal of Clinical Medicine · 2025
    9. When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review Journal of Dermatological Treatment · 2025
    10. Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2 SKIN The Journal of Cutaneous Medicine · 2025
    11. Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study SKIN The Journal of Cutaneous Medicine · 2025
    12. Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial SKIN The Journal of Cutaneous Medicine · 2025
    13. Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata Clinical Cosmetic and Investigational Dermatology · 2025
    14. 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study Journal of Investigative Dermatology · 2025
    15. 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program Journal of the American Academy of Dermatology · 2025
    16. 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program Journal of the American Academy of Dermatology · 2025
    17. Response to Pavlović ’s “Response to Li et al.’s ‘Therapeutic efficacy of platelet-rich plasma combining with microneedling and topical minoxidil in refractory severe androgenic alopecia’” Journal of the American Academy of Dermatology · 2025
    18. 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata Journal of Investigative Dermatology · 2025
    19. BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata British Journal of Dermatology · 2025
    20. <i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect Proceedings of the National Academy of Sciences · 2025
    21. Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute The Journal of Dermatology · 2025
    22. Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study Journal of Cosmetic Dermatology · 2025
    23. Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center The Journal of Dermatology · 2025
    24. Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata SKIN The Journal of Cutaneous Medicine · 2025
    25. Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata Clinical and Experimental Dermatology · 2024
    26. Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study Journal of Cosmetic Dermatology · 2024
    27. Using high-intensity phototechnology as a method of treating mild to severe diffuse alopecia Fizioterapevt (Physiotherapist) · 2024
    28. Asymptomatic SARS-COV2 Infection or COVID-19 vaccination effect for severe multisystem inflammatory syndrome in a 6-year-old girl: case report and review of the literature 2024
    29. Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study Journal of the European Academy of Dermatology and Venereology · 2024
    30. Tissue expansion and follicular unit extraction hair restoration in rehabilitation of a severe postburn deformity of neck and beard region Journal of Cutaneous and Aesthetic Surgery · 2024